Nanosphere (NASDAQ: NSPH) is one of 80 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Nanosphere to similar companies based on the strength of its profitability, analyst recommendations, earnings, valuation, institutional ownership, dividends and risk.
Institutional & Insider Ownership
51.5% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Nanosphere and its competitors top-line revenue, earnings per share and valuation.
Nanosphere’s competitors have higher revenue and earnings than Nanosphere. Nanosphere is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for Nanosphere and its competitors, as reported by MarketBeat.com.
||Strong Buy Ratings
As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 5.14%. Given Nanosphere’s competitors higher probable upside, analysts plainly believe Nanosphere has less favorable growth aspects than its competitors.
This table compares Nanosphere and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Nanosphere competitors beat Nanosphere on 6 of the 8 factors compared.
Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.
Receive News & Ratings for Nanosphere Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanosphere and related companies with MarketBeat.com's FREE daily email newsletter.